ArticleCancer research2017
Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Gaps and paths forward in cancer pharmacology and translational research.Frontiers in pharmacology · 2026Review
- Article
- Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC.Journal of experimental & clinical cancer research : CR · 2025Article
- Low-Dose Chemotherapy Preferentially Shapes the Ileal Microbiome and Augments the Response to Immune Checkpoint Blockade by Activating AIM2 Inflammasome in Ileal Epithelial Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy.Frontiers in cell and developmental biology · 2024Review
- COVID-19 vaccine incentive scheduling using an optimally controlled reinforcement learning model.Physica D. Nonlinear phenomena · 2023Article
- Organelle-inspired supramolecular nanomedicine to precisely abolish liver tumor growth and metastasis.Bioactive materials · 2022Article
- Induction chemotherapy increases efficacy and survival rate of patients with locally advanced esophageal squamous cell carcinoma.Frontiers in oncology · 2022Article
- Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach.Scientific reports · 2021Article
- Are Adaptive Chemotherapy Schedules Robust? A Three-Strategy Stochastic Evolutionary Game Theory Model.Cancers · 2021Article
- The pro-tumorigenic host response to cancer therapies.Nature reviews. Cancer · 2019Review
- The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.JCO clinical cancer informatics · 2019Article
- Nonlinear adaptive control of competitive release and chemotherapeutic resistance.Physical review. E · 2019Article
- Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment.Journal of theoretical biology · 2018Article
- Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction.Oncotarget · 2018Article
- Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.Journal of theoretical biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
We extended the classical tumor regression models such as Skipper's laws and the Norton-Simon hypothesis from instantaneous regression rates to the cumulative effect over repeated cycles of chemotherapy. To achieve this end, we used a stochastic Moran process model of tumor cell kinetics coupled with a prisoner's dilemma game-theoretic cell-cell interaction model to design chemotherapeutic strategies tailored to different tumor growth characteristics. Using the Shannon entropy as a novel tool to quantify the success of dosing strategies, we contrasted MTD strategies as compared with low-dose, high-density metronomic strategies (LDM) for tumors with different growth rates. Our results show that LDM strategies outperformed MTD strategies in total tumor cell reduction. This advantage was magnified for fast-growing tumors that thrive on long periods of unhindered growth without chemotherapy drugs present and was not evident after a single cycle of chemotherapy but grew after each subsequent cycle of repeated chemotherapy. The evolutionary growth/regression model introduced in this article agrees well with murine models. Overall, this model supports the concept of designing different chemotherapeutic schedules for tumors with different growth rates and develops quantitative tools to optimize these schedules for maintaining low-volume tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.